QuidelOrtho (NASDAQ:QDEL) Director Matthew Strobeck Buys 10,000 Shares

QuidelOrtho Corporation (NASDAQ:QDEL) Director Matthew Strobeck purchased 10,000 shares of the stock in a transaction dated Friday, February 13th. The stock was bought at an average cost of $23.96 per share, with a total value of $239,600.00. Following the completion of the purchase, the director owned 27,775 shares in the company, valued at $665,489. The trade was a 56.26% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

QuidelOrtho Trading Down 0.7%

QuidelOrtho stock traded down $0.16 during midday trading on Friday, hitting $23.58. 2,502,523 shares of the stock were exchanged, compared to its average volume of 1,177,556. The company has a fifty day simple moving average of $29.64 and a two-hundred day simple moving average of $27.73. QuidelOrtho Corporation has a 52 week low of $19.50 and a 52 week high of $42.50. The stock has a market capitalization of $1.60 billion, a PE ratio of -1.42 and a beta of 0.68. The company has a quick ratio of 0.98, a current ratio of 1.78 and a debt-to-equity ratio of 1.23.

QuidelOrtho (NASDAQ:QDEL) last posted its earnings results on Wednesday, February 11th. The company reported $0.46 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.03. The company had revenue of $723.60 million for the quarter, compared to analyst estimates of $699.80 million. QuidelOrtho had a negative net margin of 41.46% and a positive return on equity of 5.52%. The business’s revenue for the quarter was up 2.2% compared to the same quarter last year. During the same period last year, the business posted $0.63 earnings per share. Equities research analysts anticipate that QuidelOrtho Corporation will post 2.3 EPS for the current fiscal year.

QuidelOrtho News Summary

Here are the key news stories impacting QuidelOrtho this week:

• Positive Sentiment: Significant insider buying — CEO Brian J. Blaser bought 10,540 shares (~$23.59 avg) and CFO Joseph M. Busky bought 3,370 shares (~$23.66 avg), materially increasing their ownership. Insider purchases can signal management confidence in the business. CEO Form 4 CFO Form 4
• Neutral Sentiment: Q4 revenue slightly beat expectations — reported $723.6M (up ~2.2% YoY), driven by Labs and TRIAGE growth; earnings showed mixed signals with adjusted metrics differing from GAAP items. Company highlights FY25 progress and says it expects continued growth in FY26. Press Release
• Negative Sentiment: FY‑2026 EPS guidance came in below consensus — management guided $2.00–$2.42 vs. the Street ~$2.49, raising concern over near‑term profitability and prompting the selloff. Guidance Article
• Negative Sentiment: Margin pressure and respiratory weakness — analysts and deep‑dive pieces highlight shrinking gross/operating margins and product mix headwinds that weighed on profits despite revenue growth. Those concerns are central to today’s negative sentiment. Deep Dive
• Neutral Sentiment: Analyst stance is mixed-to-cautious — some firms have underweight ratings or below‑consensus targets, while the median 6‑month target sits notably above current prices, reflecting divergence on recovery prospects. Analyst Summary

Analyst Upgrades and Downgrades

QDEL has been the subject of a number of research analyst reports. Citigroup boosted their target price on QuidelOrtho from $23.00 to $30.00 and gave the company a “neutral” rating in a research note on Thursday. Zacks Research upgraded QuidelOrtho from a “strong sell” rating to a “hold” rating in a research report on Tuesday, January 13th. Weiss Ratings restated a “sell (e+)” rating on shares of QuidelOrtho in a report on Thursday, January 22nd. UBS Group set a $30.00 price target on shares of QuidelOrtho in a research note on Thursday. Finally, JPMorgan Chase & Co. lowered their price objective on shares of QuidelOrtho from $26.00 to $22.00 and set an “underweight” rating for the company in a research report on Friday, November 7th. One investment analyst has rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus target price of $31.50.

Institutional Trading of QuidelOrtho

Institutional investors have recently made changes to their positions in the business. Invesco Ltd. grew its position in QuidelOrtho by 87.0% in the third quarter. Invesco Ltd. now owns 2,906,763 shares of the company’s stock valued at $85,604,000 after purchasing an additional 1,352,503 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of QuidelOrtho by 14.0% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,859,455 shares of the company’s stock worth $84,208,000 after buying an additional 350,636 shares during the last quarter. State Street Corp boosted its stake in shares of QuidelOrtho by 1.3% during the 4th quarter. State Street Corp now owns 2,704,355 shares of the company’s stock worth $77,236,000 after buying an additional 35,616 shares during the last quarter. Newtyn Management LLC grew its holdings in shares of QuidelOrtho by 58.3% in the 3rd quarter. Newtyn Management LLC now owns 2,700,000 shares of the company’s stock valued at $79,515,000 after acquiring an additional 994,332 shares in the last quarter. Finally, American Century Companies Inc. increased its position in shares of QuidelOrtho by 10.4% in the third quarter. American Century Companies Inc. now owns 2,115,557 shares of the company’s stock valued at $62,303,000 after acquiring an additional 199,909 shares during the last quarter. Institutional investors own 99.00% of the company’s stock.

QuidelOrtho Company Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.